HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
United Kingdom Health OTC Drugs

J&J Switches Benacort Hayfever Spray From Rx To GSL Status In The UK

  • News

Executive Summary

J&J switches its Benacort hayfever nasal spray from prescription-only to general sales list status in the UK, making it the third mass market steriod-based spray available outside pharmacy.

You may also be interested in...



Sanofi’s Nasacort Hay Fever Spray Latest In Post-Brexit UK Switch Boom

Sanofi's Nasacort Allergy Relief hay fever spray is the latest in a flood of reclassifications in the UK since the beginning of the year when the country left the European Union.

Sanofi Switch Gives UK Hay Fever Sufferers Additional Mass Market Option

Sanofi has switched its Allevia hay fever tablets (fexofenadine hydrochloride) in the UK, from prescription-only to general sales list status. 

J&J Leverages Power Of Digital Personalization With Nicorette UK Extension

Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.

Table

View full table

Related Content

HBW Insight
HBW Insight
HBW Insight

Topics

Tags:
United Kingdom Health OTC Drugs
UsernamePublicRestriction

Register

RS150807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By